文献速递胸部肿瘤

英国肺癌筛查试验中新发结节的发病率与肺癌概率

Incidence and lung cancer probability of new nodules in the UK lung screening trial.
PubMed 文献 · Eur J Cancer · 2026-05-02

该研究分析UKLS随机对照试验中4055名高危个体,评估随访中新发非钙化结节的恶性风险。875名有随访CT的参与者中,131人(15%)出现216个新实性结节,总体恶性率3.8%(5/131)。12个月随访中新实性结节恶性概率随体积和VDTmax分层升高,30mm³为关键体积阈值。

要点

  • 12个月随访新实性结节恶性率7.4%,短期随访为0%。
  • 新结节恶性概率随体积增加:≥200mm³为15.4%。
  • VDTmax<50天者恶性概率达33.3%。

核心结论

  • 12个月筛查时新发实性结节的恶性风险高于短期随访,并验证30mm³为需至少进一步监测的关键体积阈值。

研究设计与样本

  • 基于UKLS多中心随机对照试验,纳入4055名50-75岁、LLPv2风险≥4.5%的高危个体,分析随访中新登记的非钙化结节。

主要发现

  • 875名有随访CT的参与者中,131人(15%)出现216个新实性结节,参与者水平恶性率为3.8%(5/131)。
  • 新实性结节发病率短期随访为17%(72/432),12个月随访为8%(68/809)。
  • 5例肺癌均在12个月随访首次检出,该时点新实性结节参与者恶性率为7.4%(5/68),短期随访为0%(0/72)。

关键数值与推荐

  • 12个月随访时,新结节体积<30mm³恶性概率0%(95%CI 0.0-21.6),30-200mm³为7.9%(95%CI 2.0-21.5),≥200mm³为15.4%(95%CI 3.1-43.5)。
  • 12个月随访时,VDTmax≥100天恶性概率2.0%(95%CI 0.0-11.7),50-100天为18.8%(95%CI 5.8-43.8),<50天为33.3%(95%CI 5.6-79.8)。

临床怎么用

  • 对12个月随访中新发实性结节应提高警惕,尤其体积≥30mm³或VDTmax<100天者需进一步监测。
  • 短期随访中新发实性结节恶性风险低,但仍需按计划随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New nodules detected during lung cancer screening follow-up have a higher average malignancy risk than same-size baseline nodules. We aimed to characterize the incidence and malignancy risk of new nodules in the UK Lung Cancer Screening Trial (UKLS). METHODS: This study analysed data from the UKLS multicenter randomized controlled trial recruiting 4055 high-risk individuals (aged 50-75 years, with a LLPv2 risk of ≥4.5%) between 2011 and 2013. Our analysis included all non-calcified nodules registered as new at short-term (3-month) or 12-month follow-up. Volume and maximum volume doubling time (VDTmax) were analysed. Lung cancer diagnoses were confirmed by histology. RESULTS: Of 875 participants with follow-up CT scans, 131 (15%) developed 216 new solid nodules, yielding an overall participant-level malignancy rate of 3.8% (5/131); no malignancies were diagnosed in new subsolid nodules. New solid nodule incidence was 17% (72/432) at short-term and 8% (68/809) at 12-month follow-up. All 5 cancers were first detected at 12-month follow-up, where 7.4% (5/68) of participants with new solid nodules had cancer, while the risk was 0% (0/72) at short-term follow-up. At 12-months, new nodule malignancy probability was stratified by volume: 0% (95% CI: 0.0-21.6) for < 30 mm³ , 7.9% (2.0-21.5) for 30-200 mm³ , and 15.4% (3.1-43.5) for ≥ 200 mm³ ; and by VDTmax: 2.0% (0.0-11.7) for ≥ 100 days, 18.8% (5.8-43.8) for 50-100 days, and 33.3% (5.6-79.8) for < 50 days. CONCLUSION: New solid nodules at 12-month screening carry higher risk than short-term, and we validate 30mm³ as the critical volume threshold requiring at least further surveillance.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jiang B, Lancaster HL, Davies MPA, et al. Incidence and lung cancer probability of new nodules in the UK lung screening trial. Eur J Cancer. 2026. PMID: 42155364. doi:10.1016/j.ejca.2026.116779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。